反応式
[CH3:1][N:2]1[C:7](=[O:8])[C:6]2[CH:9]=[CH:10][S:11][C:5]=2[N:4]([CH2:12][CH:13]([CH3:15])[CH3:14])[C:3]1=[O:16].C([N-]C(C)C)(C)C.[Li+].[C:25]([C:27]1[CH:34]=[CH:33][CH:32]=[CH:31][C:28]=1[CH:29]=[O:30])#[N:26].O>O1CCCC1>[NH:26]=[C:25]1[O:30][CH:29]([C:10]2[S:11][C:5]3[N:4]([CH2:12][CH:13]([CH3:14])[CH3:15])[C:3](=[O:16])[N:2]([CH3:1])[C:7](=[O:8])[C:6]=3[CH:9]=2)[C:28]2[CH:31]=[CH:32][CH:33]=[CH:34][C:27]1=2参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
To a solution of 3-methyl-1-(2-methylpropyl)thieno[2,3-d]pyrimidin-2,4(1H,3H)-dione (500 mg) in tetrahydrofuran (10 ml) at −78° C. was added lithium diisopropylamide (1M, 3.1 ml). After 5 minutes a solution of o-cyanobenzaldehyde in tetrahydrofuran (2 ml) was added and the reaction was allowed to stir for 2 h. Water (10 ml) was the added and the mixture was allowed to warm to room temperature. The mixture was extracted with ethyl acetate. The organic layer was separated and dried over magnesium sulfate, then concentrated in vacuo and purified by normal phase HPLC to yield the title compound (15 mg).
後処理
- additionadded
- extractionThe mixture was extracted with ethyl acetate
- customThe organic layer was separated
- dry with materialdried over magnesium sulfate
- concentrationconcentrated in vacuo
- custompurified by normal phase HPLC
出典と根拠
- ORDレコード
- ord-998a81851c3e4775950226110ecde8a5
- 出典データセット
- uspto-grants-2001_01
- 特許番号
- US06180635B2
関連ノート
読み込み中…